3D腹腔镜与2D腹腔镜在前列腺癌根治术中的对比:回顾性队列研究（英文）  

Three-dimensional versus two-dimensional imaging systems in laparoscopic radical prostatectomy for prostate cancer:a retrospective cohort study

作　　者：唐开强[1] 庞诗语 包继明[1] 类成勇[1] 谭万龙[1] 

机构地区：[1]南方医科大学南方医院泌尿外科,广东广州510515

出　　处：《南方医科大学学报》2017年第1期1-5,共5页Journal of Southern Medical University

摘　　要：目的对3D腹腔镜与2D腹腔镜在前列腺癌根治术中的围手术期结果、功能性及肿瘤相关性结果进行比较。方法从2014年2月至2016年1月,72位临床局限性前列腺癌患者接受了腹腔镜下前列腺根治术,手术均由同一名有经验的术者操作完成。收集及评估患者的临床基本特征,围手术期结果,功能及肿瘤相关结果。结果 36位病人接受了3D腹腔镜前列腺癌根治术,另外36位病人接受了2D腹腔镜前列腺癌根治术。3D腹腔镜组比2D腹腔镜组手术时间短(167 min vs 218 min,P<0.001),平均出血量少(86.11 m L vs 177.78 m L,P<0.001),且两组术后3个月尿控率有统计学差异(88.89%vs 63.89%,P=0.026)。两组间手术并发症、性功能恢复及无生化复发率无明显差异。结论与2D腹腔镜下前列腺癌根治术相比,3D腹腔镜下前列腺癌根治术的手术时间更短,出血更少,术后早期尿控情况更好。Objective To compare the perioperative, functional and oncologic outcomes of patients with prostate cancer receiving laparoscopic radical prostatectomy （LRP） using three-dimensional （3D） versus two-dimensional （2D） imaging systems. Methods From February, 2014 to January 2016, 72 consecutive patients with clinically localized prostate cancer underwent LRP with 2D or 3D imaging systems performed by a single experienced surgeon. The baseline characteristics, perioperative data, and functional and oncologic outcomes of the patients were collected and analyzed. Results Thirty-six patients underwent 3D LRP and the other 36 patients underwent 2D LRP. Compared with 2D LRP group, 3D LRP group had a significantly shorter operative time （167 vs 218 min, P〈0.001）, a smaller volume of intraoperative blood loss （86.11 vs 177.78 mL, P〈0.001） and a better early urinary continence outcome （88.89% vs 63.89%, P=0.026）. No significant differences were found between the two groups in terms of complications, potency outcome or biochemical recurrence-free rate. Conclusion Compared with 2D LRP, 3D LRP shortens the operative time, reduces intraoperative blood loss and is associated with a better early urinary continence outcome in patients with clinically localized prostate cancer.

关 键 词：3D腹腔镜 2D腹腔镜 腹腔镜下前列腺癌根治术 

分 类 号：R737.25[医药卫生—肿瘤]